Since Henry left Congress in 2015, his office has changed but his mission has not. That truth was reflected in a recent profile in The Washington Post that highlighted his ongoing struggle to ensure pharmaceuticals are well-regulated and accessible to the patients that need them most. In Congress, that meant passing the Affordable Care Act, creating the generic drug industry, and incentivizing the development of orphan drugs. At Waxman, that fight continues with our work to protect the 340B drug pricing program, which provides drug discounts to safety net providers, from cuts.
From the article: “We’re doing everything we can for [hospitals], from messaging to traditional public relations and advocacy… I am willing to advocate for clients whose causes I support, and I definitely support the cause of the 340B program.”
Read more in The Washington Post.